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We describe a new approach for infectious disease
surveillance that facilitates rapid identification of known and
emerging pathogens. The process uses broad-range poly-
merase chain reaction (PCR) to amplify nucleic acid targets
from large groupings of organisms, electrospray ionization
mass spectrometry for accurate mass measurements of
PCR products, and base composition signature analysis to
identify organisms in a sample. We demonstrate this princi-
ple by using 14 isolates of 9 diverse Coronavirus spp.,
including the severe acute respiratory syndrome–associat-
ed coronavirus (SARS-CoV). We show that this method
could identify and distinguish between SARS and other
known CoV, including the human CoV 229E and OC43,
individually and in a mixture of all 3 human viruses. The
sensitivity of detection, measured by using titered SARS-
CoV spiked into human serum, was ≈1 PFU/mL. This
approach, applicable to the surveillance of bacterial, viral,
fungal, or protozoal pathogens, is capable of automated
analysis of >900 PCR reactions per day.
N
ucleic acid tests for infectious diseases are primarily
based on amplification methods that use primers and
probes designed to detect specific organisms. Because
prior knowledge of nucleic acid sequence information is
required to develop these tests, they are not able to identi-
fy unanticipated, newly emergent, or previously unknown
infectious organisms. Thus, the discovery of new infec-
tious organisms still relies largely on culture methods and
microscopy, which were as important in the recent identi-
fication of the severe acute respiratory syndrome–associat-
ed coronavirus (SARS-CoV) as they were in the discovery
of HIV 2 decades ago (1–4).
Broad-range polymerase chain reaction (PCR) methods
provide an alternative to single-agent tests. By amplifying
gene targets conserved across groups of organisms, broad-
range PCR has the potential to generate amplification prod-
ucts across entire genera, families, or, as with bacteria, an
entire domain of life. This strategy has been successfully
used with consensus 16S ribosomal RNAprimers for deter-
mining bacterial diversity, both in environmental samples
(5) and in natural human flora (6). Broad-range priming
has also been described for detection of several viral fami-
lies, including CoV (7), enteroviruses (8), retroid viruses
(9), and adenoviruses (10). The drawback of this approach
for epidemiologic applications is that the analysis of PCR
products for mixed amplified samples requires sequencing
hundreds of colonies per reaction, which is impractical to
perform rapidly or on large numbers of samples. New
approaches to the parallel detection of multiple infectious
agents include multiplexed PCR methods (11,12) and
microarray strategies (13–15). Microarray strategies are
promising because undiscovered organisms might be
detected by hybridization to probes designed to conserved
regions of known families of bacteria and viruses. 
We present an alternative approach for rapid, sensitive,
and high-throughput detection of infectious organisms. We
use broad-range PCR to generate amplification products
from the broadest possible grouping of organisms, followed
by electrospray ionization mass spectrometry and base
composition analysis of the products (16,17). The base
compositions of strategically selected regions of the
genome are used to identify and distinguish organisms in
the sample. Enhanced breadth of priming is achieved
through the use of primers and probes containing 5-propy-
nyl deoxycytidine and deoxyuridine nucleotides that offer
increased affinity and base pairing selectivity (18,19).
Positioning the 5-propynyl primidine-modified nucleotides
at highly conserved positions enables priming at short con-
sensus regions and significantly increases the extent to
which broad groups of organisms can be amplified.
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CoV Isolates and Broad-range PCR Primer Pairs
Table 1 lists all the CoV used in this study. Multiple
sequence alignments of all available CoV nucleotide
sequences from GenBank were scanned to identify pairs of
potential PCR priming loci. Two target regions were
selected in CoV ORF-1b (annotations based on Snijder et
al. [20]), 1 in RNA-dependent RNA polymerase (RdRp)
and the other in Nsp14 (Table 2). 5′ propynyl-modified
pyrimidine nucleotides (shown in bold) were positioned at
universally conserved positions within these primers to
extend the breadth of broad-range priming to allow effi-
cient PCR from all CoV species tested. 
For each primer region, a database of expected base
compositions (A, G, C, and T base counts) from all known
CoV sequences in GenBank was generated (data not
shown) and used in the identification and classification of
the test isolates. Several of the isolates used in this study
did not have a genome sequence record in GenBank.
Experimentally measured base compositions from these
isolates were independently verified by sequencing ≈500
bp regions that flanked both target regions used in this
study (GenBank accession nos. AY874541 and AY878317–
AY878324). 
RNA Extraction, Reverse Transcription, and PCR
RNAwas isolated from 250 µLof CoV-infected cells or
culture supernatant spiked with 3 µg of sheared poly-A
DNA using Trizol or Trizol LS, respectively (Invitrogen
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protocol. Reverse transcription was performed by mixing
10 µL of the purified RNAwith 5 µL of water treated with
diethyl pyrocarbonate (DEPC, Sigma-Aldrich Co., St.
Louis, MO, USA) containing 500 ng random primers, 1 µg
of sheared poly-A DNA, and 10 U SUPERaseIn (Ambion
Inc., Woodlands, TX, USA). The mixture was heated to
60°C for 5 min and then cooled to 4°C. Following the
annealing of the random primers to the RNA, 20 µLo f
first-strand reaction mix consisting of 2x first-strand buffer
(Invitrogen Inc.), 10 mmol/L DTT, 500 µmol/L deoxynu-
cleoside triphosphates (dNTPs), and 7.5 U SuperScript II
was added to the RNA primer mixture. The RNA was
reversed transcribed for 45 min at 45°C. Various dilutions
of the reverse transcription reaction mixes were used
directly in the PCR reactions.
All PCR reactions were performed in 50 µL with 96-
well microtiter plates and M.J. Dyad thermocyclers (MJ
Research, Waltham, MA, USA). The PCR reaction buffer
consisted of 4 U Amplitaq Gold (Applied Biosystems,
Foster City, CA USA), 1x buffer II (Applied Biosystems,
Foster City, CA, USA), 2.0 mmol/L MgCl2, 0.4 mol/L
betaine, 800 µmol/L dNTP mix, and 250 nmol/L propyne-
containing PCR primers. The following PCR conditions
were used to amplify CoV sequences: 95°C for 10 min fol-
lowed by 50 cycles of 95°C for 30 s, 50°C for 30 s, and
72°C for 30 s. After PCR, the amplified products were
desalted before analysis by electrospray ionization Fourier
transform ion cyclotron resonance mass spectrometry
(ESI-FTICR-MS) by methods described previously (21). A
small oligonucleotide SH2 (CGTGCATGGCGG,
Synthetic Genetics, San Diego, CA, USA) was added as an
internal mass standard (22); the final concentration of SH2
was 50 nmol/L.
Mass Spectrometry and Signal Processing
The mass spectrometer used in this work is based on a
Bruker Daltonics (Billerica, MA, USA) Apex II 70e ESI-
FTICR-MS that used an actively shielded 7 Tesla super-
conducting magnet. All aspects of pulse sequence control
and data acquisition were performed on a 1.1 GHz
Pentium II data station running Bruker’s Xmass software
(Bruker Daltonics). Inputs to the signal processor are the
raw mass spectra for each of the parallel PCR reactions
used to analyze a single sample. The ICR-2LS software
package (23) was used to deconvolute the mass spectra and
calculate the mass of the monoisotopic species using an
“averagine” fitting routine (24) modified for DNA(Drader
et al., unpub. data). Using this approach, monoisotopic
molecular weights were calculated. The spectral signals
were algorithmically processed to yield base composition
data as described previously (25). The amplitudes of the
spectra are calibrated to indicate the number of molecules
detected in the mass spectrometer versus m/z and the m/z
values are corrected by using internal mass standards. The
algorithm computes the organism’s identity and abun-
dances consistent with observations over all the PCR reac-
tions run on the input sample.
Results and Discussion
Detection of Individual CoV Isolates 
For broad-range detection of all CoV, the 2 PCR primer
target regions shown in Table 2 were used against each
virus listed in Table 1. Resultant products were desalted
and analyzed by FTICR-MS by methods described previ-
ously (21). The spectral signals were algorithmically
processed to yield base composition data. Figure 1 shows
a schematic representation of electrospray ionization,
strand separation, and the actual charge state distributions
of the separated sense and antisense strands of the PCR
products from the RdRp primer pair for SARS-CoV. Due
to the accuracy of FTICR-MS (mass measurement error
± 1 ppm), all detected masses could be unambiguously
converted to the base compositions of sense and antisense
strands (25). 
One of the limitations of all molecular methods for
detecting pathogens, including the one described here, is
that unexpected variations in PCR primer target sequences
in unknown species can lead to missed detection. To min-
imize this possibility, the primers designed in this study
were selected on the basis of highly conserved regions
identified by multiple sequence alignments of all previous-
ly known CoV species sequences. Further, we chose 2
amplification targets for redundant detection of the CoV
and to have increased resolution to distinguish the
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against multiple isolates from the 3 previously known CoV
species groups and from SARS-CoV isolates.
The results from analysis of 14 CoV isolates are shown
in Table 1. For both target regions, the measured signals
agreed with compositions expected from the known CoV
sequences in GenBank. Several of the isolates used in this
study did not have a genome sequence record in GenBank.
Nevertheless, we were able to amplify all test viruses and
experimentally determine their base compositions. These
experimentally determined base compositions were con-
firmed by sequencing (data not shown). Thus the strategy
described here enables identification of organisms without
the need for prior knowledge of the sequence, provided
that the broad range primers do not fail to amplify the tar-
get because of excessive numbers of mismatches.
Multiple CoV Isolates in Mixture
To demonstrate the potential to detect multiple viruses
in the same sample, as might occur during a coinfection,
we pooled the viral extracts from 3 human CoV, HCoV-
229E, HCoV-OC43, and SARS-CoV, and analyzed the
mixture. Signals from all 3 viruses were clearly detected
and resolved in the mass spectra (Figure 2), which demon-
strated that coinfections of >1 CoV species could be iden-
tified. We have previously determined that the system can
reliably detect multiple species in ratios of ≈1:1,000, while
varying input loads from 10 to 10,000 organisms (data not
shown).
Sensitivity 
To determine sensitivity in a clinical sample, viable,
titered SARS-CoV was added to human serum and ana-
lyzed in 2 ways. In the first, RNAwas isolated from serum
containing 2 concentrations of the virus (1.7 x 105 and 170
PFU/mL), reverse transcribed to cDNA with random
primers, and serially diluted (10-fold), before PCR ampli-
fication with both RdRp and Nsp14 primer sets. By using
this approach, the assay was sensitive to ≈10-2 PFU
per PCR reaction (≈1.7 PFU/mL serum). We estimated
the number of reverse-transcribed SARS genomes by
competitive, quantitative PCR with a nucleic acid internal
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Figure 1. Electrospray ionization Fourier transfer ion
cyclotron resonance (ESI-FTICR) mass spectrum
from the polymerase chain reaction (PCR) amplicons
from the severe acute respiratory syndrome (SARS)-
associated coronavirus obtained with the propynyla-
ted RNA-dependent RNA polymerase primer pairs.
The electrospray ionization conditions separate the
sense and antisense strands of the PCR products.
Multiple charge states are observed across the m/z
range shown. The inset shows an expanded view of
the isotope envelope of the (M-27H+)27- species. As
enumerated in Table 1, the derived molecular mass-
es for the amplicon strands are 27298.518 (+0.03)
Da and 27125.542 (+0.03) Da, corresponding to an
unambiguous base composition of A27G19C14T28/
A28G14C19T27 for the double-stranded amplicon,
the composition expected for the SARS isolate.
Figure 2. Detection of 3 human coronaviruses (CoV) in a mixture.
The deconvoluted (neutral mass) mass spectra obtained for the
RNA-dependent RNA polymerase primer for the 3 human CoV,
HCoV-229E, HCoV-OC43, and severe acute respiratory syn-
drome-associated CoV, which were tested individually and in a
mixture, are shown. Forward and reverse amplicons are shown
with the measured monoisotopic masses for each strand. Colors
of the monoisotopic masses for the mixed spectra correspond to
the individual viral species. standard (data not shown). Analysis of ratios of mass spec-
tral peak heights of titrations of the internal standard and
the SARS cDNA showed that ≈300 reverse-transcribed
viral genomes were present per PFU, similar to the ratio of
viral genome copies per PFU previously reported for RNA
viruses (26). By using this estimate, PCR primers were
sensitive to 3 genome equivalents per PCR reaction, which
is consistent with previously reported detection limits for
optimized SARS-specific primers (27,28). In the second
method, we spiked 10-fold dilutions of the SARS virus
into serum before RT-PCR and could reliably detect 1 PFU
(≈300 genomes) per PCR reaction or 170 PFU (5.1 x 104
genomes) per mL serum. The discrepancy between the
detection sensitivities in the 2 experimental protocols
described above suggests that losses were associated with
RNA extraction and reverse transcription when very little
virus was present (<300 genome copies) in the starting
sample in serum. This finding is consistent with results for
direct measurement of RNA viruses from patient samples
(26). Therefore, in a practical experimental analysis of a
tissue sample, the limit of sensitivity was ≈1 PFU per PCR
reaction.
RNA Virus Classification with Base Compositions
We have described a novel approach using base compo-
sition analysis for viral identification. However, since
RNA virus nucleotide sequences mutate over time within
the functional constraints allowed by selection pressure
(29), the utility of this method to correctly classify RNA
viruses depends on the resolution needed for a particular
application. We considered 2 specific applications. The
first was to distinguish SARS-CoV from other species of
CoV that infect humans, namely HCoV-OC43 and HCoV-
229E. The second application was the utility of the tech-
nique for exploration of animal reservoirs for the discovery
of SARS-related CoV species. 
To quantitatively analyze the resolving power of base
compositions, we mathematically modeled base composi-
tion variations using known sequences of multiple isolates
of hepatitis C virus (HCV) in GenBank (H. Levene et al.,
unpub. data). HCV sequence-derived mutation probabili-
ties were used to estimate the extent of base composition
variations for CoV species. Figure 3 shows a plot of the
base compositions for the RdRp target region for the 3 CoV
known to infect humans. ∆bc represents the net changes in
composition required for strain variants of 229E or OC43 to
be misidentified as SARS, and ∆m the probability of occur-
rence of these changes. The cumulative probability of mis-
classifying either 229E or OC43 as SARS by using base
composition measurements from both target regions was
low (∆m >10), even allowing for unseen variations in those
2 viruses. Thus, for use in human clinical diagnostics, base
composition analysis of the 2 target regions described here
would provide corroborative information and accurate
species identification of CoV infections.
To determine the utility of base composition analysis in
the search for animal CoV species, we calculated the
cumulative mutation distances for both target regions for
all known CoV and plotted groups where all members fall
within certain probability thresholds, as shown in Figure 4.
A series of nested ovals represents subgroupings of
species, where the maximal distance between known
members of a subgroup is represented by the ∆m next to the
oval. By using the above classification metric, SARS-CoV
would be considered the first member of a new group of
CoV, not a member of the core group 2 cluster, although it
would be placed closest to group 2 (∆m < 10.2). These find-
ings are similar to those recently described by Snijder et
al., who used sequence data from the replicase genes
(5,487 bp) in ORF1b and suggested that the SARS-CoV
was most closely related to and possibly an early split-off
from group 2 CoV (20). However, substantial space exists
around SARS-CoV where as yet undiscovered SARS-CoV
could populate a subgroup without being confused with the
group 2 or other CoV. 
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Figure 3. Spatial representation of base compositions for the 3
coronavirus (CoV) species known to infect humans. Severe acute
respiratory syndrome (SARS), HCoV-OC43, and HCoV-229E
base compositions in the region amplified by RNA-dependent
RNA polymerase primers (Table 1) are plotted on the A, G, and C
axes. T counts are shown by the tilt of the symbol. Within a
species, all known isolates of each virus (37 isolates for SARS, 4
for HCoV-229E, and 2 for OC43) had identical sequences in this
region. ∆bc represents the number of changes in the A, G, C, and
T bases needed for 1 species to be misidentified as another in the
direction of the arrow. ∆m represents the pairwise mutation dis-
tance between 2 species, or the cumulative probability of ∆bc
occurring.Conclusion
The strategy we describe allows rapid identification of
new viral species members of previously characterized
viral families, without the need for prior knowledge of their
sequence, through use of integrated electrospray ionization
mass spectrometry and base composition analysis of broad-
range PCR products. Broad-range PCR reactions are capa-
ble of producing products from groups of organisms, rather
than single species, and the information content of each
PCR reaction is potentially very high. Further, in many
cases, including the SARS-CoV detection described in this
article, priming across broadly conserved regions provides
adequate species detection and taxonomic resolution. In
cases where additional subspecies level classification
becomes important, broad primers can be followed up with
more species-specific primers that can detect even single
nucleotide changes (SNPs) or alternatively, larger regions
of the identified species can be analyzed by sequencing.
Despite the advances in high throughput sequencing, how-
ever, it is impractical as a front-end detector in a routine
survey and detection setting. The mass spectrometer is
capable of analyzing complex PCR products at a rate of ≈1
minute per sample. Because the process is performed in an
automated, microtiter plate format, large numbers of sam-
ples can be examined (>900 PCR reactions/day/instru-
ment), which makes this process practical for large-scale
analysis of clinical or environmental surveillance samples
in public health laboratory settings. The current generations
of ESI mass spectrometers used in the detector cost approx-
imately U.S.$150,000 and can be operated 24 hours per day
by trained technicians. Tools for analyzing mass spectrom-
etry data are widely available and are described in detail
elsewhere (23–25). A comparable alternative to the meth-
ods described here are microarrays, which can also provide
broad range detection.
This approach can be extended to other viral, bacteri-
al, fungal, or protozoal pathogen groups and is a powerful
new paradigm for timely identification of previously
unknown organisms that cause disease in humans or ani-
mals and for monitoring the progress of epidemics.
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